PRAX
Praxis Precision Medicines, Inc.
There isn't enough reported data to score PRAX yet.
PRAX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PRAX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
PRAX PE Valuation
PRAX has no meaningful PE right now: it lost money over the past year.
PRAX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PRAX's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
PRAX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$12.82 | +$0.02 |
| Q2 2026 | -$12.95 | -$0.72 |
| Q1 2026 | -$13.39 | -$2.73 |
| Q4 2025 | -$13.48 | -$3.27 |
| Q3 2023 | -$33.45 | +$43.65 |
| Q2 2023 | -$45.15 | +$32.55 |
| Q1 2023 | -$57.60 | +$13.50 |
| Q4 2022 | -$69.60 | -$10.50 |
PRAX is still losing money, but far less than before: $12.82 per share over the past year, against $77.70 at its worst in mid-2022.
PRAX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $7.5M | +1349% |
| Q3 2024 | $302K | -35% |
| Q2 2024 | $357K | -54% |
| Q1 2024 | $431K | -37% |
PRAX's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -857% | +4542 points |
| Q3 2024 | -18820% | -13367 points |
| Q2 2024 | -10501% | -6025 points |
| Q1 2024 | -9718% | -4141 points |
| Q4 2023 | -5399% | N/A |
| Q3 2023 | -5452% | N/A |
| Q2 2023 | -4476% | N/A |
| Q1 2023 | -5577% | N/A |
PRAX's operating margin was −857% last quarter, up 4542 points from the same quarter a year ago.
PRAX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$83.3M | -$18.2M |
| Q1 2026 | -$86.2M | -$33.2M |
| Q3 2025 | -$65.1M | -$37.6M |
| Q1 2025 | -$53M | -$32.2M |
| Q3 2024 | -$27.5M | -$4.3M |
| Q2 2024 | -$27.3M | +$3.9M |
| Q1 2024 | -$20.9M | +$12M |
| Q4 2023 | -$23.9M | +$4.9M |
PRAX has burned cash in almost every quarter: −$324M over the past year, against −$173M the year before.
PRAX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +47K shares |
| 1 year | +33% | +7.2M shares |
| 3 years | +528% | +24.5M shares |
| 5 years | +953% | +26.4M shares |
PRAX has 29M diluted shares, up 33% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | $30M |
| Q4 2019 | — |
PRAX Net Leverage
PRAX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PRAX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.5 | Neutral |
| Stochastic | 38.0 | Neutral |
PRAX's weekly RSI is 54 (neutral) and its Stochastic is 38 (neutral).
PRAX PE vs Healthcare Sector
PRAX has no meaningful PE right now: it lost money over the past year.
PRAX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $277.4 | 17% above |
| 20 week MA | $312.2 | 4% above |
| 50 week MA | $309.1 | 5.1% above |
| 100 week MA | $189.4 | 71% above |
| 200 week MA | $113.8 | 185% above |
PRAX is in an uptrend: it's above all five of its weekly moving averages, and 185% above its 200-week average.
PRAX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $417.0 | $790.1 | +89% |
| 2021 | $790.1 | $309.2 | -61% |
| 2022 | $309.2 | $36.3 | -88% |
| 2023 | $36.3 | $22.3 | -39% |
| 2024 | $22.3 | $77.0 | +246% |
| 2025 | $77.0 | $269.0 | +249% |
| 2026 YTD | $269.0 | $324.8 | +21% |
PRAX's yearly returns have swung widely, from +249% in 2025 to −88% in 2022. It's up 21% so far in 2026.